Health Delegates Blog

Unlocking Savings: The Power of Transparent Reporting

healthdelegatesteam@gmail.com (Health Delegates) — Wed, 05 Feb 2025 19:35:05 GMT

The Power of Transparent Reporting in Pharmacy Benefits

Managing pharmacy benefit costs is one of the most complex challenges faced by benefits managers, large employer groups, and health plans consultants. As prescription drug prices continue to rise, finding a way to efficiently manage pharmacy spending and maximize savings is crucial. While rebate programs can offer significant savings, many traditional models lack the transparency and granularity needed to fully understand where savings are coming from—and where they may be slipping through the cracks.

At Health Delegates, we’ve revolutionized rebate management with a robust online reporting suite that delivers unparalleled visibility into pharmacy spend, empowering health plans and employer groups to optimize their benefits programs and increase their savings. With over 4 million covered lives under our management, we have the experience and expertise to handle diverse requirements with precision and care.

Effective Rebate Management through Transparent Reporting

One of the core strengths of Health Delegates lies in our ability to offer a 360-degree view of your pharmacy spending. Our reporting suite is designed to give you thorough, real-time insights into how and where rebates are earned, down to the net cost of each claim. This transparency paves the way for smarter, more informed decision-making when it comes to managing pharmacy benefits.

Whether you’re looking to track rebate performance, improve formulary strategies, or optimize drug savings, our reporting tools provide actionable data that allows you to make savings decisions with confidence.

Our Approach: Simplifying Cost Management

At Health Delegates, we take a straightforward approach to rebate solutions. Our goal is to provide a clear picture of your overall pharmacy benefit costs, so you can make data-driven decisions that optimize savings. We understand that balancing rebates, clinical formulary solutions, and broader healthcare costs can be complex. That’s why we offer a comprehensive solution that enables you to manage all these factors effectively, with a focus on reducing your net drug costs.

We aim to be your strategic partner , delivering the insights you need to optimize your pharmacy benefits and maximize your rebate opportunities. With our suite of customizable reports, you can easily drill down into essential data and identify opportunities for savings.

Key Reporting Tools to Maximize Savings

Health Delegates offers a suite of customizable, client-centric reports that give you a transparent and comprehensive understanding of your pharmacy spending. Here’s an overview of the key reports we provide:

Executive Summaries

Our executive summaries offer a concise yet thorough overview of your rebate management, summarizing key data points, performance trends, and areas for improvement. This high-level report gives health plans and employer groups an easily digestible snapshot of their rebate program’s effectiveness, helping you make informed decisions and adjust strategies where needed.

Operational Reports

Our operational reports provide critical insights into the details of your claims. This includes reports on claim submissions, rejected claims, and the reasons behind rejections. These reports are standardized for easy integration into your data warehouse or analytics engine, making it simple to manage rebates and address anomalies as they occur.

Financial Reports

Timely and accurate financial forecasting is essential for budgeting and planning. Health Delegates provides financial reports that provide estimates of expected rebates, as well as detailed tracking of specific rebate payments received. These reports enable transparent tracking of funds and their sources, drilling down to the claim level, including NDC, to demonstrate the direct value of your rebate program.

Clinical Reports

Our clinical reports analyze formulary product distribution and provide insights into which drugs are being used most frequently. This helps identify how drug utilization impacts overall rebate earnings and provides valuable data for formulating clinical program strategies. These insights are essential for adjusting formularies and ensuring you’re maximizing rebate potential.

Maximize Your Pharmacy Savings with Health Delegates

Health Delegates is committed to helping health plans and employer groups unlock the full potential of their pharmacy benefit programs through transparent, detailed reporting. Our tools empower you to make better-informed decisions, optimize your drug spending, and drive greater savings—all while maintaining the high standards of care your members expect.

Ready to optimize your pharmacy benefits? Contact us at hdinquiries@healthdelegates.com today to learn how our comprehensive reporting and innovative rebate solutions can help you take control of your pharmacy spending.

Healthcare Integrity: Investigating the Ethical Dilemmas of Co-Manufacturing

healthdelegatesteam@gmail.com (Health Delegates) — Fri, 08 Nov 2024 20:11:33 GMT

FTC Targets PBM Practices Amid Rising Drug Costs

In the ongoing quest to address skyrocketing drug prices, Senators Ron Wyden and Sherrod Brown have taken a significant step forward by urging the Federal Trade Commission (FTC) to investigate potentially anti-competitive practices by parent companies of major pharmacy benefit managers (PBMs). Central to their concerns are the obscure yet emerging “co-manufacturing” agreements. While these agreements might initially seem like standard industry practice, they could be concealing efforts by these companies to monopolize more segments of the pharmaceutical supply chain, inevitably leading to limited drug options and higher costs for consumers. The implications of these practices necessitate a vigilant approach from regulators to ensure that the market remains competitive and fair, prioritizing consumer welfare over corporate profits.

Investigating the Ethical Dilemmas of Co-Manufacturing

Lawmakers are increasingly alarmed by the co-manufacturing agreements forming between certain parent company PBMs and pharmaceutical manufacturers. These strategic alliances permit these companies to invest in medication production directly, thereby securing rebate deals that predominantly serve their financial objectives. This intertwining of production and benefit management gives them undue influence, potentially guiding patients toward drugs that benefit the company’s bottom line instead of focusing on patient outcomes or cost-effectiveness . The ethical quandary here is profound: Are these companies operating as impartial gatekeepers in the healthcare system, or are they profit-driven entities manipulating choice and availability? The FTC’s investigation into these practices is pivotal, as it will help reveal how such maneuvers affect consumer access to affordable, effective medications.

The Impact on Drug Prices and Consumer Choice

The issue at hand extends beyond just ethical concerns; it reaches into the very pockets of American consumers. By controlling which medications are promoted or available, these companies can significantly influence pricing and availability in the market. This control could stifle competition by favoring drugs produced under co-manufacturing agreements, even if they are not the most cost-effective or clinically effective options available. Such practices could also limit the ability of smaller drug manufacturers to compete, potentially reducing innovation and consumer choice in the long run.

Our Mission: Revolutionizing Healthcare Management

At Health Delegates, we are committed to transforming the healthcare landscape through innovative, client-centered rebate solutions. We strive to create a balanced healthcare environment that merges cost efficiency with superior clinical results. Our approach involves transparent rebate processes, customized formulary and benefit designs, and advanced data analytics. By enabling our clients to make well-informed decisions, we enhance healthcare benefits management, ensuring both accessibility and affordability for all. Our dedication extends to being a reliable guide through the complex terrain of rebate management, armed with integrity, expertise, and an unwavering commitment to community health and well-being.

Expanding Our Vision: Transparent Healthcare Solutions

In light of the complexities and potential conflicts of interest presented by traditional rebate models, Health Delegates advocates for a more transparent and equitable system. We believe in empowering our clients with clear information and straightforward choices. Our models are designed to eliminate hidden fees and reduce the opaque curtain that often surrounds drug pricing and rebate agreements. By focusing on transparency, we help ensure that every dollar spent is going toward improving health outcomes and not into the pockets of intermediaries with conflicting interests.

Join Us in Building a more equitable Healthcare Future

If you are eager to learn more about how Health Delegates can assist you in navigating the complexities of healthcare management and rebate strategies , contact us at hdinquiries@healthdelegates.com for more information on our services and how we can help create a more equitable healthcare system together. Your journey towards better health outcomes for all starts with the right partnerships and strategies, and at Health Delegates, we are here to lead the way.

Staying Informed: The Key to Navigating Complex Rebate Models

healthdelegatesteam@gmail.com (Health Delegates) — Wed, 28 Aug 2024 13:09:11 GMT

Staying Informed: The Key to Navigating Complex Rebate Models

New Lawsuits Shed Light on the Need for Transparent Rebate Models

Recent lawsuits have underscored the critical need for transparency and accountability in pharmacy benefit management (PBM) financial dealings. These cases have sparked concern about the risks associated with complex PBM contracts, prompting organizations to reevaluate their practices. When it comes to managing pharmacy benefits, rebates are a critical component and without clarity in rebate models , employers may find themselves entangled in hidden fees, ambiguous terms, and uncertain outcomes. Health Delegates straightforward rebate solution and detailed reporting will leave no uncertainty.

Staying Informed: The Key to Navigating Complex Rebate Models

In an industry that evolves rapidly, staying informed is essential to making the right decisions. The intricacies of rebate models can leave organizations uninformed about how their funds are managed. At Health Delegates, we prioritize keeping our clients informed, providing clear and consistent updates to help you navigate these complexities confidently. By empowering you with knowledge, we enable you to stay ahead of the curve and make decisions that benefit your organization.

Understanding Your Fiduciary Responsibility

As an employer or plan sponsor, you have a fiduciary responsibility to manage your organization’s resources wisely, including pharmacy benefits. Ensuring that you obtain the best value from your rebate model is not only good practice but also a legal requirement. The recent lawsuits highlight the consequences of neglecting fiduciary duties. With Health Delegates , you can trust that our transparent rebate model aligns with your fiduciary obligations, offering clear terms that safeguard your organization’s interests.

Health Delegates: Assisting in Managing Drug Costs with a Clinical Focus

Effective drug cost management requires a blend of financial strategy and clinical insight. At Health Delegates, we understand the importance of delivering the lowest net cost while ensuring the highest clinical value. Our rebate mode l is designed with this dual focus, providing cost-effective solutions that prioritize patient care. By aligning financial incentives with clinical outcomes, we help you achieve optimal results both financially and clinically.

Health Delegates: Delivering Results and Driving Growth

Experience the difference with a partner dedicated to delivering results and driving growth. Since 2013, Health Delegates has been at the forefront of providing transparent rebate models , setting new standards in pharmacy benefit management. Our impact is substantial, managing rebate and clinical solutions for over 4 million covered lives. This achievement demonstrates our ability to handle extensive and diverse requirements with precision and care.

The total rebates we’ve collected reflect our commitment and expertise. Our approach is grounded in deep industry knowledge, customized to meet your unique needs, and focused on delivering the best possible outcomes. Choose a partnership with Health Delegates that not only promises but also delivers proven results, fostering continuous growth in your pharmaceutical management strategies.

Discover the Health Delegates Difference

If you would like to learn more about how Health Delegates' transparent rebate model can benefit your organization, we invite you to reach out to us. Contact us at hdinquiries@healthdelegates.com to explore how we can help you manage drug costs while ensuring the highest clinical value for your organization.

Rethinking Rebate Models: Transparency and True Cost Savings

healthdelegatesteam@gmail.com (Health Delegates) — Tue, 30 Jul 2024 18:46:46 GMT

Discover how Health Delegates offers a transparent rebate model that ensures true cost savings without the pitfalls of traditional rebate guarantees.

In today's complex healthcare landscape, the promise of a rebate guarantee often falls short of its intended benefits. While touted as a means to lower net costs, rebate guarantee-based contracts frequently obscure the true financial picture and lack transparency. These agreements, often rife with manipulated definitions and exclusions, may serve the interests of aggregators and Pharmacy Benefit Managers (PBMs), rather than those of Payers and Plan Sponsors. Amidst these challenges, Health Delegates stands out with a commitment to a better rebate model—one that prioritizes clarity and genuine savings.

Shedding Light on Rebate Guarantees

Rebate guarantees have become a cornerstone of many pharmacy benefit contracts, fostering a dependency on rebate dollars. Employers and benefit consultants, in their selection of PBMs, often rely on these guarantees to project cost savings. However, the reality is far from straightforward. Guarantee based rebate contracts while seemingly advantageous, frequently mask the actual net prices of drugs. This opacity can lead to the inclusion of higher-cost products in formularies, ultimately inflating total pharmacy costs rather than reducing them. Not to mention that if the actual rebate exceed s the promised amount, the excess is often retained, adding a layer of complexity and potential confusion due to the less transparent nature of the financial flows and rebate calculations.

The Pitfalls of Traditional Models

The common occurrence of rebate guarantees raises significant concerns. By prioritizing these guarantees, employers risk losing visibility into true net prices and may inadvertently support inflated drug costs. This practice not only complicates financial forecasting but also undermines efforts to streamline healthcare expenditures effectively. The result? Higher overall costs and a disconnect between projected savings and actual outcomes.

A Better Way Forward with Health Delegates

At Health Delegates, we believe in a different approach. Our rebate model is built on transparency and accountability, ensuring that our clients benefit from clear, measurable savings. Our company employs a pass-through payment system where all rebates received from pharmaceutical manufacturers are directly passed on to our clients, such as insurers or employers, without any exclusions or ambiguous definitions. This model ensures complete transparency, allowing clients to benefit fully from the financial rebates, potentially leading to lower insurance premiums or reduced costs for plan members. The clarity and directness of this model make it straightforward and reliable.

By using our pass-through mode l, clients enjoy a clear and unambiguous financial benefit, avoiding the complexities and potential confusion inherited by a guarantee model.

Partner with health delegates

If you're ready to discover a rebate model that works for you, reach out to Health Delegates. Email us at hdinquiries@healthdelegates.com to learn more about how we can transform your pharmacy benefit strategy. Join us in reshaping healthcare economics through transparency and effective cost management.

Health Delegates: We Are More Than Just Rebates

healthdelegatesteam@gmail.com (Health Delegates) — Wed, 10 Jul 2024 17:16:01 GMT

Addressing the Problem: High Cost, Low Value Drugs

In today's complex healthcare landscape, managing medication costs while ensuring optimal patient care is a significant challenge. High-cost, low-value drugs can easily slip through the cracks, inflating healthcare expenses without providing corresponding benefits. This issue not only strains healthcare budgets but also impacts patient outcomes. Effective solutions are essential to navigate this problem, ensuring that resources are allocated to treatments that truly make a difference.

Health Delegates: A Comprehensive Approach

Health Delegates' services extend far beyond just rebates. We are committed to enhancing healthcare value through strategic management of spending on the pharmacy benefit. By negotiating rebates and offering innovative solutions, we help payers achieve significant cost savings without compromising the quality of care. Our approach ensures that every dollar spent on medications delivers the maximum possible value.

Three Proprietary Formularies: Anchor, Apex, and Aspire

At the heart of our offerings are our three proprietary formularies : Anchor, Apex, and Aspire. Each formulary is meticulously designed to cater to different healthcare needs and priorities.

Anchor : An open formulary that focuses on providing a robust foundation of clinical products, ensuring accessibility and affordability.
Apex : Narrows the scope, prioritizing treatments that offer significant clinical and financial benefits through exclusionary lists.
Aspire : Our innovative closed formulary, embracing high clinical value products while marrying low net cost factors, focusing on a generics-first policy to ensure cost-effective treatment options are utilized first.

Together, these formularies offer options to payers to balance cost and quality of care through flexible management.

Comprehensive Utilization Management Program

Alongside our formularies, we offer utilization management options. This program is crucial for ensuring appropriate utilization of products and preventing high-cost, low-value drugs from being overlooked. By employing rigorous evaluation processes and evidence-based guidelines, we ensure that only the most effective and necessary medications are approved. These P&T committee-approved options help to optimize therapeutic outcomes while controlling costs, making healthcare more sustainable and patient-centric.

Partner with health delegates

Is your rebate program providing you with a comprehensive program to address your specific needs? Partner with Health Delegates and leverage our expertise to maximize your healthcare value. Discover how our proprietary formularies and comprehensive utilization management can transform your pharmacy strategy. Contact us today!

Shifting Focus: Driving Low Net Cost in Pharmacy Benefits Management

Wed, 26 Jun 2024 17:22:08 GMT

A recent insightful article in The New York Times delves into the complexities and challenges of prescription drug costs and the role of Pharmacy Benefit Managers (PBMs). The piece highlights how traditional PBM models often prioritize high rebates, which can sometimes lead to higher overall drug costs and misaligned incentives.

At Health Delegates , we recognize these issues and take a fundamentally different approach. Our mission is to drive towards the lowest net cost for our clients rather than chasing high rebates. Here’s how we stand apart:

Health Delegates’ Unique Approach

Transparent Rebate Strategy:

We focus on clear and straightforward contracting terms. Our goal is to ensure that our clients understand the true costs and savings associated with their pharmacy benefits, eliminating hidden fees and complex rebate structures that obscure the real costs.

Decoupled PBM Services Model:

By utilizing a decoupled PBM services approach, our clients separate the rebate management from the other functions of pharmacy benefits management utilizing Health Delegates for formulary, clinical, and rebate support. This model ensures that incentives are not misaligned, as it segregates the administration of drug benefits from the negotiation of drug prices. This separation allows us to assist our clients more effectively and avoid conflicts of interest inherent in traditional PBM models.

Focus on Lowest Net Cost:

Our primary objective is to achieve the lowest net cost for our clients. We prioritize overall drug spend reduction over high rebates. This involves diligent management of formulary design, utilization management, benefit drug list management, and drug pricing to minimize total costs while maintaining high standards of care.

Decreasing Trend:

By focusing on the lowest net cost, we help our clients decrease their trend on overall drug spend. This includes proactive management of drug utilization and adherence to evidence-based guidelines, ensuring that patients receive the most appropriate therapies at the best possible cost.

Independent P&T Committee:

Health Delegates features an independent Pharmacy and Therapeutics (P&T) committee. This committee, free from the influence of rebate-driven decisions, ensures that formulary choices are based on clinical evidence and patient outcomes. This clinical flexibility allows for better control over drug utilization and enhances the ability to provide the best possible care at the lowest cost.

Benefits of Our Approach

Alignment of Incentives:

With a decoupled PBM services model, clients can be confident that our incentives are aligned with theirs and not with a global view. This alignment ensures that we are always working towards the common goal of reducing overall costs while improving patient outcomes.

Enhanced Transparency:

Our approach fosters transparency, providing our clients with clear insights into their pharmacy benefits spend and the factors driving those costs. This, in turn, allows our clients to meet their goals and objectives for their offerings.

Improved Cost Management:

By focusing on low net cost rather than high rebates, we deliver more sustainable and predictable cost management. This helps our clients to better plan and budget for their pharmacy benefits.

Clinical Flexibility:

Our independent P&T committee ensures that formulary decisions are made based on clinical efficacy and patient needs, allowing for better management of drug utilization and improved patient outcomes.

cost management goals

Navigating the complexities of pharmacy benefits management requires a strategic approach that prioritizes true cost savings over superficially attractive rebate guarantees. At Health Delegates, our commitment to transparency, fitting into a decoupled PBM services model, and a focus on the lowest net cost sets us apart. We invite you to learn more about how our unique approach can benefit your organization and help you achieve your cost management goals.

For more information on how Health Delegates can support your pharmacy benefits management needs, please contact us today.

Drug Manufacturer Rebates: Claims Reporting & Simplifying the Process

healthdelegatesteam@gmail.com (Health Delegates) — Wed, 29 May 2024 17:41:52 GMT

Unlocking the Complexity of Rebates

Navigating the world of rebates can leave you feeling confused and frustrated. The complex nature of these rebates obscures their origins, leaving you unsure about where your rebates are truly coming from. The lack of visibility into individual claims and the long list of exclusions further exacerbate the issue. Guarantees, which may or may not be met, add another layer of uncertainty, leaving you in the dark about what counts towards these guarantees and what does not. The Health Delegates model can bring clarity and transparency to this complex landscape.

Decoupling Rebates:

One of the primary challenges in managing rebates lies in the bundling of these rebates with other network discounts and claims processing, including formulary and clinical services. This bundling process complicates accounting and accountability, making it increasingly difficult to track and manage rebate programs effectively.

At Health Delegates, we advocate for the decoupling of these programs to ensure transparency and accountability. By separating rebates from other network discounts and claims processing, we streamline the process, allowing for clearer visibility into rebate structures and ensuring that every dollar is accounted for and maximized.

Transparency and Accountability: Reporting of Drug Rebates

Understanding rebates and guarantees can be purposefully confusing since the bundling of claims cannot be evaluated at an individual level. At Health Delegates, we address this specific challenge head-on with detailed reporting, straightforward contracts, and regular communication with our clients. Our approach allows us to track rebate activity at the claim level, providing unparalleled visibility into rebate returns. We also work with our clients to ensure their formulary and benefit designs are maximizing their cost savings. We create our own formularies to work for our clients and can also support custom designs. With our expertise and ability to drill down into individual claims, we empower stakeholders to take control of their rebate programs and optimize their outcomes.

Empowering Stakeholders: A Path to Transparent and Effective Rebate Solutions

At Health Delegates , we are committed to working with our clients to decouple rebates and provide stakeholders with transparent and effective rebate solutions. Our comprehensive online reporting tools and team of industry experts ensures that clients have the insights and support they need to navigate rebate programs successfully. Additionally, our formulary services help align clients for optimal efficacy and cost-effectiveness, further maximizing the value of rebate programs. With Health Delegates by your side, you can confidently navigate the intricate world of rebates and unlock substantial savings for your organization.

Take Control of Your Rebates: Schedule a Consultation Today

Ready to take control of your rebate programs and unlock substantial savings for your organization? Schedule a consultation with Health Delegates for an in-depth analysis of your group's needs and drug utilization. Discover how our transparent and effective rebate solutions can help you maximize savings and optimize outcomes. Don't let the complexity of rebate contracts hold you back—take the first step towards clarity and transparency today.

Navigating the Complexities of Benefits Management: The Case for Transparency and Alignment

healthdelegatesteam@gmail.com (Health Delegates) — Wed, 20 Mar 2024 18:35:06 GMT

In the intricate landscape of corporate benefits management, navigating the array of consulting services and pharmacy benefit managers (PBMs) presents its own set of challenges. Opting for consolidated solutions promises simplicity and efficiency on the surface but often conceals a deeper issue: the risk of misaligned incentives leading to inflated costs and compromised benefits management.

Understanding the Pitfalls of Consolidated Solutions

The allure of streamlined services through a single provider or consultant is understandable, aiming to reduce administrative burdens and potentially harness cost savings. Yet, this approach can inadvertently foster a setting where the interests of consultants or PBMs do not fully align with those of the company and its employees. Recently filed court cases accuse employers of overpaying for prescription drugs, exemplifies the possible neglect in securing competitive pricing, hinting at a broader issue of oversight.

Compensation models for consultants that tie back to the volume or cost of procured services and medications can, albeit unintentionally, favor higher-cost options. This structure may prioritize the consultant's financial gain over the best interests of the company and its workforce, clouding the cost-effectiveness and benefits of management decisions and potentially undermining the fiduciary duty owed to employees.

The Advantages of a Decentralized Approach to Benefits Management

Choosing a decentralized model for managing benefits introduces multiple benefits, including:

Competitive Pricing Assurance : Engaging with various providers for different benefits aspects allows for effective comparison and ensures optimal value.
Improved Transparency: A decentralized model offers clearer insight into the costs and benefits of each package component, vital for budget management and justifying employee benefits.
Fiduciary Duty Compliance : Critical evaluation and selection of benefits components align with the company’s responsibility to act in the best interests of its employees.

Strategies for Effective Benefits Management

Adopting a thoughtful approach to avoid misaligned incentives and honor fiduciary duties involves several key actions:

Routine Audits : Regular evaluations of benefits plans can spotlight inflated costs or misalignments with employee needs.
Diverse Vendor Engagement : Collaborating with multiple vendors encourages competitive pricing and terms.
Transparent Vendor Selection : A clear and competitive vendor selection process ensures the identification of the best services and prices available.

The recently filed case against J&J serves as a valuable lesson for companies to scrutinize their benefits management approach. While consolidated services offer appeal, it’s crucial to be mindful of potential misalignments and the significance of maintaining a competitive and transparent environment. Shifting towards a decentralized strategy can better align with employee interests, uphold fiduciary responsibilities, and unveil potential cost savings.

Explore Decentralized Solutions with Health Delegates

Facing the complexities and possible conflicts of consolidated benefits management, companies can benefit from expert guidance in this area. Health Delegates specializes in assisting companies with decoupling and decentralizing pharmacy benefits, ensuring alignment with fiduciary responsibilities and optimizing value and cost-effectiveness for employees.

Reevaluating your benefits strategy with a focus on decentralization could enhance transparency, competitive pricing, and fiduciary duty compliance. Health Delegates is poised to support you in this journey, offering customized solutions that cater to your unique needs and objectives.

Reach out to Health Delegates to discover how we can aid in refining your pharmacy benefit management and rebate strategies . Our expertise is designed to navigate the intricacies of benefits management, aligning your approach with your organizational values and the well-being of your employees.

Enhancing Partnership through Transparent Contracting Practices

healthdelegatesteam@gmail.com (Health Delegates) — Tue, 05 Mar 2024 16:02:11 GMT

Pharmacy Benefit Managers (PBMs) are invaluable partners in the healthcare industry, orchestrating prescription drug benefits for health insurers, Medicare Part D drug plans, and large employers. Their role is pivotal in navigating the complex landscape of healthcare to deliver efficient and cost-effective drug benefit management. Recognizing the challenges in PBM contracts, this blog aims to highlight the mutual benefits of fostering transparency, clarity, customization, and a client-centric approach in our partnerships. By focusing on these areas, we can collaboratively address the needs of providers, consumers, and the entire healthcare ecosystem.

Advancing Transparency in PBM Contracts

A foundation of trust and partnership in the healthcare industry begins with transparency. While there have been concerns regarding the clarity around rebate amounts, drug pricing, and pharmacy service costs, advancing transparent contracts can greatly benefit all parties involved. Transparent contracts that offer clear insights into drug pricing, rebates , and fees not only foster trust but also enable employers and patients to make informed decisions. Encouraging an environment where financial transactions and potential conflicts of interest are openly discussed can lead to better outcomes for everyone in the healthcare value chain.

Promoting Clear Definitions and Customization

The significance of having clear definitions within PBM contracts cannot be overstated. Ambiguities around terms such as 'generic drugs', ' specialty drugs ', and 'rebates' can lead to misunderstandings. Ensuring that these terms are precisely defined will help in eliminating confusion and fostering a more transparent relationship. Additionally, recognizing the unique needs of each employer or health plan is critical. A tailored approach to PBM services, including formulary design, drug utilization reviews, and pharmacy network design, can address specific needs more effectively, leading to enhanced efficiency and cost management.

Embracing Client-Centric Management

Adopting a client-centric management approach places the focus squarely on the needs of employers, health plans, and patients. This strategy ensures that PBMs' incentives are aligned with the clients' objectives, such as achieving cost savings, ensuring high-quality care, and improving patient outcomes. A commitment to regular performance reviews, efficient drug spend management, and exceptional customer service are key to a successful client-centric strategy. Such an approach not only benefits clients but also strengthens the partnership between PBMs and their stakeholders.

Navigating Legal Challenges and Collaborative Solutions

The evolving legal landscape, exemplified by cases like Rutledge v. Pharmaceutical Care Management Association, underscores the importance of collaboration between PBMs, states, and federal entities in navigating regulatory challenges. These legal precedents highlight the need for a balanced approach to regulation that supports fair reimbursement practices and acknowledges the complex interplay between state and federal laws. By working together, we can find solutions that ensure fairness and transparency while respecting the diverse regulatory frameworks.

Pharmacy Benefit Managers are essential to creating a more efficient and equitable healthcare system. By embracing practices that prioritize transparency, clarity, customization, and a client-centric focus, we can strengthen our partnerships and achieve shared goals. The journey towards reforming PBM practices is a collaborative effort, requiring engagement from all stakeholders in the healthcare system. Together, we can advocate for and implement changes that enhance the well-being of all parties involved and contribute to a healthier future for everyone.

Forge Ahead Together:

Collaborative Action with Health Delegates

Pharmacy Benefit Managers are central to fostering a more efficient and equitable healthcare system. By embracing practices that emphasize transparency, clarity, customization, and a client-centric approach, we can significantly strengthen our partnerships and achieve our collective goals. The path to reforming PBM practices is one that we must walk together, engaging all stakeholders in the healthcare system to advocate for and implement meaningful changes. It's through collaboration that we can ensure a healthier future for everyone.

At Health Delegates , we are committed to going beyond the industry norm. We believe in the power of teamwork and market responsiveness to secure the best possible outcomes for our partners:

Beyond Rebate Guarantees: We transcend traditional rebate guarantees, focusing instead on dynamic market adaptation and delivering real value. Our dedicated team works tirelessly to ensure you receive the best possible rebates. For us, it's not about arbitrary numbers; it's about delivering tangible results and fostering long-term partnerships.
Simplified Contracting: We understand the complexities of PBM contracts and strive to offer straightforward rebate solutions. Our approach cuts through the clutter of exclusions and complex guarantees, providing the flexibility to make formulary and rebate decisions that genuinely benefit your plan. We aim to harmonize financial and clinical decisions, tailoring our services to meet your unique needs.
Retain Full Control and Visibility: With Health Delegates, you maintain complete visibility and control over the financial aspects of your plan. Every rebate, administrative fee, and price protection measure is passed directly through to you, ensuring transparency, eliminating surprises, and building trust.

We invite you to reach out to Health Delegates to explore how we can work together to navigate the complexities of PBM and rebate contracts and achieve a more transparent, efficient, and equitable healthcare system. Let's join forces to create solutions that are not only beneficial but also sustainable for all parties involved. Contact us today to learn more about how we can support your goals and foster a thriving partnership.

The Future of Medicine: Cell and Gene Therapies in 2024

healthdelegatesteam@gmail.com (Health Delegates) — Tue, 20 Feb 2024 13:46:58 GMT

Introduction to Cell and Gene Therapies

Cell and gene therapies represent a frontier in medical innovation, offering new hope for diseases once deemed incurable. These advanced treatments involve altering the genetic material within a patient's cells to treat or prevent disease. In 2024, we are witnessing an unprecedented era in these therapies, marked by rapid advancements and increasing clinical applications.

The Essence of CGTs

Cell therapy involves the transplantation of living cells into a patient to replace or repair damaged tissue or cells. Gene therapy, on the other hand, involves modifying the genetic material within a patient's cells to treat or prevent disease. Together, these therapies offer a new paradigm in medicine – treating the root cause of diseases at the molecular level.

The Evolution of CGTs

Since the first successful gene therapy trials in the 1990s, the field has evolved dramatically. Early challenges, such as immune reactions and questions about efficacy, have given way to a new era of sophisticated techniques and a better understanding of genetic mechanisms. Recent advancements have been bolstered by parallel developments in technologies like CRISPR-Cas9, which allows for precise editing of the genome.

Advances in Gene Therapy and AI Integration

Breakthroughs in Gene Therapy

In 2023, the gene therapy field witnessed significant advancements, notably with the FDA approval of cell-based gene therapies for treating sickle cell disease. These therapies, Casgevy and Lyfegenia, signify a monumental leap, particularly with Casgevy being the first CRISPR-based therapy to receive FDA approval. This approval not only represents a breakthrough in treating sickle cell disease but also paves the way for genome editing technologies to treat a wide range of genetic disorders.

AI's Transformative Role

AI is significantly advancing gene therapy development. It plays a critical role in creating personalized treatment plans by analyzing individual genetic biomarkers. This personalized approach is essential for treating rare diseases, where one-size-fits-all solutions are ineffective. AI-driven bioinformatics and genetic sequencing are enabling more targeted and effective therapies, tailored to each patient's unique genetic makeup.

The Rising Success of CAR-T Cell Therapy

CAR-T cell therapy, a form of immunotherapy that uses modified T cells to attack cancer, has shown remarkable success, particularly in treating blood cancers. This therapy involves reengineering a patient's own immune cells to recognize and destroy cancer cells. In 2024, there's an expectation that the application of CAR-T cell therapy will extend beyond blood cancers to solid tumors, like colon and ovarian cancer. This expansion highlights the potential of cell therapies in treating a diverse range of diseases.

The Expanding Horizons of CAR-T

The success of CAR-T cell therapy in blood cancers has been a beacon of hope and a clear demonstration of the power of cellular immunotherapy. The transition into treating solid tumors is a complex endeavor due to the different nature of these cancers compared to blood cancers. However, ongoing research and clinical trials are showing promising results, potentially revolutionizing the treatment of solid tumors.

Managing Costs and Innovative Payment Models

Tackling High Costs

One of the primary challenges with CGTs is their high cost, driven by complex manufacturing processes and the personalized nature of these treatments. This presents a significant barrier to accessibility, making it difficult for many patients to afford these life-saving therapies.

Innovative Payment Solutions

To mitigate these financial challenges, innovative payment models are being explored. These include outcomes-based payments, where a portion of the therapy cost is covered upfront and the remainder is paid if the therapy achieves specific outcomes. Other models include rebates for therapies that fail to meet predefined outcomes and annuities spread over multiple payments, contingent on continued therapeutic efficacy.

The Future Landscape of CGTs

Broadening Therapeutic Applications

CGTs are not limited to genetic diseases and cancers. Researchers are exploring their applications in metabolic, genetic, and central nervous system disorders. Most of these applications are in early stages, but they hold the promise of expanding the range of treatable conditions significantly.

Market Growth and Challenges

The global market for CGTs is expected to see substantial growth, with projections of significant sales by 2029. Oncology is expected to continue leading the development of CGTs. Despite this growth, the field faces ongoing challenges such as high development costs, clinical trial failures, and increasing pricing pressures. Addressing these issues is crucial for realizing the full potential of CGTs.

The landscape of cell and gene therapies in 2024 is one of rapid advancement and significant potential. These therapies are on the brink of transforming medicine, offering new treatments for a range of diseases. The integration of AI and innovative payment models are key to overcoming current challenges, and the future of these therapies is bright with the potential to treat diseases more effectively and personally than ever before.

Subscribe for additional news in healthcare innovation

As we stand on the cusp of a new era in healthcare, the journey of cell and gene therapies is just beginning. The advancements in 2024 and beyond promise not just to transform our industry, but to redefine what is possible in the treatment of previously incurable diseases. However, the true power of this revolution lies in our ability to share, learn, and grow together. If you're as inspired by the potential of these therapies as we are, and you're eager to stay at the forefront of this groundbreaking field, we invite you to join our community. Subscribe to Health Delegates and follow us for more insightful updates, cutting-edge research findings, and insight on innovation. Together, let's embark on this exciting journey into the future of healthcare, where every discovery brings us closer to a world of healthier possibilities. Don't miss out on the next breakthrough—subscribe and follow us today for a future where innovation and partnership know no bounds.

Unveiling the Hidden Costs of International Drug Sourcing

healthdelegatesteam@gmail.com (Health Delegates) — Tue, 06 Feb 2024 20:24:11 GMT

In the complex world of prescription drug management, Pharmacy Benefit Managers (PBMs) and payers are constantly seeking pathways to reduce costs and improve access to medications for their members. International drug sourcing has emerged as a promising avenue, potentially offering significant savings on expensive brand-name medications. However, this strategy also brings to light the intricate balance between immediate cost savings and the longer-term financial implications and other access issues. This blog explores the nuanced landscape of international sourcing and its true cost.

The Appeal of International Sourcing

International sourcing of medications, often seen as a cost-saving measure, allows PBMs and payers to procure drugs at a fraction of the domestic price. Countries like Canada and certain European nations have been popular sources due to their lower drug prices, which can be attributed to government price controls and negotiation policies that are absent in the U.S. market. This approach promises immediate financial relief by reducing the direct cost of brand-name medications, which are a significant expenditure for many health plans.

International Sourcing conundrums

As time has passed more payers have moved to use international sourcing. This has brought about unforeseen challenges in areas not necessarily contemplated when first implemented. Payers have begun to experience shortages in products that they were driving to international sourcing. This has lead to some of the volume moving stateside and thus increased costs associated with the products which have experienced these shortages. Payers have also begun to experience increases in pricing from their international sourcing vendors. The increased prices are a direct result of the increased volume driven through the vendors. Additionally, Canada and other European countries have started to notice supply issues for their citizens due to sourcing those drugs to payers in the United States. This has started the conversation of what is the volume that can be sent out of their country and do they want to continue to allow this as it may impact their own healthcare system. Clinically it can often be difficult to to work through issues with strengths, incorrect drugs, different drug names and more when sourcing from another country. This can potentially lead to clinical issues of subpar clinical treatment.

The Rebate Conundrum

While the upfront cost savings from international sourcing can be attractive, they come with a hidden trade-off: the potential loss of pharmacy rebates . Rebates have become a cornerstone of the current PBM and payer ecosystem, serving as a key negotiating tool with pharmaceutical manufacturers. These rebates, which can amount to a significant portion of a drug's list price, are often used by PBMs and payers to offset other costs or pass on to downstream plans, thereby reducing premiums and out-of-pocket expenses for members. The shift towards international sourcing could lead to a decrease in rebate income, impacting the overall financial health of health plans and potentially leading to increased costs elsewhere.

Evaluating the True Cost

The decision to pursue international sourcing must be informed by a comprehensive understanding of its financial implications. Beyond the immediate savings, PBMs and payers need to consider the potential financial implications which include a myriad of factors based on their international source and reduction in rebate income, which has been a critical component of their revenue and cost management strategies. This evaluation must also take into account the administrative costs associated with setting up and managing international sourcing programs, which can erode some of the expected savings. Finally it's important to look at the overall net cost of these products to ensure that decisions are being appropriately made for products. While low net cost decisions are critical to the decision it's also imperative to ensure that the clinical merits of the decision are considered as outlined above.

The Need for Strategic Balance

For PBMs and payers, finding the right balance between leveraging international sourcing for cost savings and maintaining the benefits of pharmacy rebates is crucial. This may involve selective international sourcing that targets only specific high-cost medications for which the net savings are clearly beneficial. It also calls for a strategic approach to rebate negotiations, ensuring that the value captured through rebates or other strategic formulary and coverage decisions continues to support the financial sustainability of health plans.

Reimaging Rebates

The exploration into international drug sourcing reveals a complex interplay between immediate cost savings and the broader financial implications for PBMs and payers. As the industry continues to evolve, it's imperative for these stakeholders to carefully assess the true cost of such sourcing strategies, considering both the potential savings and the impact on a payers financial outlook. We encourage PBMs and payers to delve deeper into this analysis and engage with Health Delegates to review their current strategies, ensuring they maximize the value for their members while maintaining financial health. The path forward requires a nuanced understanding of the costs and benefits, aiming for a healthcare model that is both cost-effective and sustainable.

Breaking Down the ADHD Drug Shortage: A Healthcare Emergency Unfolds

Tue, 30 Jan 2024 20:19:41 GMT

The Growing Crisis of Drug Shortages

The healthcare sector is facing a daunting challenge with the ongoing shortage of ADHD stimulant medications, a situation that has far-reaching implications for millions of individuals. This crisis began over a year ago and has since escalated, deeply affecting those dependent on these medications for managing ADHD and related conditions. The result is a complex and distressing situation where the supply of these crucial medications falls short of the growing needs, leaving patients and their families in a state of uncertainty and hardship. The consequences of this shortage extend beyond mere inconvenience, significantly impacting the daily lives, academic achievements, and mental health of those affected.

Why Are Drug Shortages Increasing?

The increasing shortages of ADHD stimulant medications are driven by a combination of supply chain issues, regulatory constraints, and shifts in healthcare practices. Initially, disruptions in manufacturing, notably at Teva Pharmaceuticals, were a key trigger. The shift in healthcare to telehealth during the COVID-19 pandemic further compounded the problem by making it easier for patients to receive ADHD diagnoses and prescriptions, leading to a surge in demand that the industry struggled to meet.

This crisis is further complicated by regulatory factors, particularly for controlled substances like many ADHD medications. The DEA imposes strict production quotas to prevent misuse, but these can unintentionally restrict the ability to rapidly respond to increased demand. This situation creates a challenging environment for manufacturers, who must balance regulatory compliance with the need to meet rising patient needs.

As a result, the pharmaceutical industry is facing a tough challenge in aligning production with the growing demand for ADHD medications. The interplay of these factors – supply chain disruptions, changes in healthcare delivery, and regulatory limits – has led to a persistent shortage, significantly impacting patients who depend on these medications for their daily lives and mental well-being. This shortage not only affects those directly in need of these drugs but also has broader implications for healthcare systems and patient care strategies.

Stimulant Shortages and Their Widespread Impact

Impact on College and School Environments

The impact of ADHD medication shortages on college and school environments is profound and multifaceted. For college students, these shortages mean grappling with heightened challenges in concentration, time management, and overall academic performance. The inability to access necessary medication can lead to decreased academic efficiency, increased anxiety, and difficulties in managing coursework. In school settings, the ripple effect is noticeable not only in the students who require these medications but also in the classroom dynamics. Teachers face challenges in managing students' attention and behavior, which can disrupt the learning environment for everyone. This situation has a cascading effect, influencing the overall educational experience and outcomes for both the affected students and their peers. The shortages thus represent not just a healthcare issue but a significant educational concern, impacting the academic journey and well-being of countless students.

Mental Health Ramifications

The ADHD medication shortage has significant mental health ramifications for those affected. The unavailability of these essential drugs can lead to increased levels of stress, anxiety, and depression, particularly for individuals who rely on these medications for daily functioning and mental health stability. The uncertainty and difficulty in accessing necessary medication can exacerbate ADHD symptoms, leading to challenges in personal, academic, and professional domains. This can result in a sense of helplessness and a decrease in quality of life. Moreover, untreated or inadequately managed ADHD can increase the risk of secondary mental health issues, such as social isolation and low self-esteem. The mental health impact of this shortage highlights the necessity for timely resolution and underscores the need for alternative support mechanisms during this challenging period.

Economic Implications: Short-Term and Long-Term Costs

The economic implications of the ADHD medication shortage are extensive, impacting both short-term and long-term costs. In the short term, patients and families are facing increased prices for ADHD drugs, a direct consequence of the limited supply. A USA Today article reported a significant rise in the cost of these medications, with some prices nearly doubling since October 2022. This increase places a substantial financial burden on those needing these medications, often forcing them to choose between costly brand-name drugs or going without treatment.

In the long term, the shortage could lead to broader market shifts. As manufacturers adjust to the increased demand and potentially invest in expanding production capabilities, the cost of these drugs could remain high. This scenario suggests that even when the shortage is resolved, the financial impact may continue to be felt by patients and the healthcare system. Additionally, the ongoing struggle to obtain medications can lead to increased healthcare expenses in other areas, such as the management of exacerbated symptoms or the use of alternative treatments.

When Will the ADHD Medication Shortage Be Resolved?

Predicting when the ADHD medication shortage will be resolved is complex and uncertain. Factors such as supply chain stabilization, regulatory adjustments, and increased manufacturing capacity play crucial roles. The FDA and DEA are actively collaborating with manufacturers to address the supply issue, but there is no definitive timeline for resolution. The challenge is compounded by unprecedented demand and the need for regulatory bodies to adjust production quotas in response to this demand. Until these issues are fully addressed, stakeholders, including healthcare providers, patients, and policymakers, must navigate an uncertain landscape, highlighting the need for adaptive strategies and continued advocacy for increased production and streamlined regulatory processes.

Role of Payers, PBMs, and Health Plans in Addressing the ADHD Medication Shortage

Payers, PBMs, and health plans play a pivotal role in supporting their members during the ADHD medication shortage. They can help by actively monitoring the drug supply and keeping members informed about availability. Flexibility in formulary management can allow for the substitution of alternative medications when necessary. Additionally, implementing policies that reduce the administrative burden for prescribers and patients, such as streamlining prior authorization processes, can be beneficial. Collaborating with healthcare providers to develop and disseminate guidelines for alternative therapies and treatment plans is also crucial. Furthermore, they can assist in advocating for regulatory changes to increase drug production and supply. By taking these proactive steps, they can significantly alleviate the challenges faced by individuals affected by the shortage.

The Evolution of GLP-1s in Weight Loss Treatment

Thu, 25 Jan 2024 16:27:14 GMT

The landscape of weight loss treatments has grown and evolved in the past few decades. Historically, options were limited, often focusing on lifestyle changes, surgical interventions, or medications with a modest efficacy and safety profile. However, recent years have seen a paradigm shift , particularly with the advent of GLP-1 (glucagon-like peptide-1) agonists. These treatments not only offer improved efficacy and safety but also align with a deeper understanding of obesity as a complex, chronic medical condition rather than a lifestyle issue packed with stigma and shame. This post explores the growth of GLP-1s, the introduction of new drugs like Zepbound, and the broader impacts of weight loss on health plans and employers. It also examines the prevailing trends in weight management in 2024 and demonstrates how Health Delegates can help you navigate formularies and rebates associated with GLP-1s.

Historical Context of Weight Loss Treatment Coverage

The journey of weight loss treatments has been fraught with challenges and skepticism, particularly regarding coverage by health insurance plans. Traditionally, many insurers were reluctant to cover weight loss medications, viewing obesity as a lifestyle choice rather than a medical condition. This perception led to limited access to effective treatments for many individuals struggling with obesity. Over time, with growing evidence of the biological underpinnings of obesity and the efficacy of new treatment options, there has been a gradual shift in this stance.

Expansion of the GLP-1 Market to Meet Demand

GLP-1 agonists have revolutionized weight loss treatment due to their efficacy and safety profile. This market is set for significant expansion with key players like Novo Nordisk, Roche, Pfizer, Amgen, and Merck intensifying efforts on GLP-1 related therapies. For instance, Novo Nordisk's data indicating high retention rates (40%) for Wegovy users underscores the drug's effectiveness and patient adherence. This retention rate is crucial, considering the chronic nature of obesity and the need for long-term, sustainable treatment options. In addition to Wegovy, some of the other GLP-1 agonists currently prescribed for weight loss include: Trulicity, Byetta, Ozempic, Victoza, and, most recently, Zepbound.

Zepbound entered the market with a staggering 25,000 new prescriptions weekly by the end of 2023 and has quickly become a significant contributor to the evolving landscape of weight loss treatment. While some manufactures are planning expansion to keep up with the demand, health plans excluding weight loss drugs from their formularies may put a damper on that growth.

Weight Loss Treatment Shift Forces Formulary Decisions

While 40% of commercial plans in the United States currently cover GLP-1 products for obesity, another 19% of plans are considering coverage . While this sounds promising, drug benefit consultants who said they don't expect many employers to start covering the drugs since the plans cannot afford it. Some plans are putting restrictions in place, only covering GLP-1 treatment for people who are severely obese, or for those who also participate in a diet and exercise program. Additionally, some plans place limits on how long members can receive the treatment.

The State of North Carolina’s decision to drop new weight loss drug coverage is one example of the financial strain faced by employers and health plans. This move, driven by rising drug costs, is expected to yield considerable savings in rebates but also underscores the escalating challenge of providing effective weight loss treatments within budgetary constraints, a trend that is quickly becoming a growing national public health concern.

Trends in Weight Loss and Health for 2024

As we begin the new year, the influence of GLP-1s is evident in various aspects of weight management, including surgery. Insurers are increasingly covering bariatric surgery , likely as a counterbalance to the high demand and costs associated with GLP-1s. This trend indicates that while GLP-1s present a viable non-surgical route for weight loss, surgery remains a potent alternative, albeit one with higher upfront costs.

Looking ahead, the obesity treatment landscape faces both challenges and opportunities. The rising cost of GLP-1s, coupled with the financial constraints of health plans, poses a

significant hurdle. However, this also opens avenues for innovation in drug development and cost management strategies. We anticipate that the focus will shift toward more cost-effective formulations, potentially including oral GLP-1s, and exploring comprehensive treatment approaches that combine medication with lifestyle changes.

Inform Formulary Decisions with Health Delegates as Your Strategic Partner

The realm of weight loss treatment is undergoing a significant transformation, led by the emergence of GLP-1 agonists. The introduction of new treatments alongside the economic implications for health plans and employers, marks a new era in obesity management.

Health Delegates can help you understand the impact of this changing environment. As your strategic partner, we’ll empower you to make the best formulary decisions for your members without any games or hidden agendas. Contact us today to learn more about our no-nonsense approach to optimizing your plan’s financials without adding to your workload.

Navigating Drug Rebates Post American Rescue Plan Act

Wed, 15 Nov 2023 15:43:00 GMT

Navigating the New Terrain of Drug Rebates Post-American Rescue Plan Act

The American Rescue Plan (ARP) Act of 2021 is set to initiate a paradigm shift not just in Medicaid rebates but across the entire spectrum of pharmaceutical rebates. This legislative change is expected to ripple through the healthcare industry, altering the dynamics of drug pricing and manufacturer rebates in a way that stakeholders must carefully navigate.

The end of rebate cap: a broader perspective

The ARP Act's removal of the statutory cap on rebates that drug manufacturers pay marks a seismic shift that extends its tremors beyond Medicaid, affecting the entire pharmaceutical rebate ecosystem. With the removal of the cap. manufacturers will face a new financial reality where the potential for rebate payments could exceed the previous 100% average manufacturer price (AMP) limit, compelling a reevaluation of pricing strategies across manufacturers. This policy change is expected to incentivize manufacturers to prevent price hikes beyond inflation rates, as any significant increase could lead to a proportionally larger rebate obligation. The industry must now prepare for a more complex rebate negotiation process, as payers may expect greater flexibility, concessions, and lower AMP considering the uncapped rebate potential. This will lead to lower rebate payments for those adjusted AMP products.

The ripple effect on brand drugs: an industry-wide impact

The uncapping of rebates is poised to have its most pronounced effect on brand drugs, particularly those with high list prices or those that have historically been at the AMP rebate cap. For manufacturers, this could translate into a steep increase in rebate liabilities, potentially reshaping the profitability landscape for certain high-cost drugs. The broader impact on the market could lead to increased competition among manufacturers to avoid the high rebate costs, possibly driving down drug prices overall. Stakeholders across the healthcare system, including pharmacies, insurers, and patients, will need to stay informed as these pricing changes could affect everything from formulary decisions to out-of-pocket costs.

Proactive measures by manufacturers: a strategic shift

In response to the ARP Act, manufacturers are likely to explore various strategies to mitigate increased rebate liabilities, such as adjusting list prices and exploring alternative pricing models. Lowering list prices, while maintaining overall net cost, could become a common approach to manage the balance between maintaining market share and controlling rebate expenses.

Manufacturers are also considering restructuring their discount programs, potentially leading to a reduction in the volume of discounts offered to maintain a sustainable Best Price. The industry could witness an increased focus on value-based pricing agreements, where reimbursement is tied to patient outcomes rather than volume, to navigate the updated rebate landscape.

Health Delegates' approach: adapting to industry-wide changes

Health Delegates is proactively adjusting its pricing models to reflect the anticipated changes inWAC and rebate amounts, ensuring transparency and predictability for their clients. By incorporating these changes into their pricing strategies now, Health Delegates is positioning itself as a leader in the transition to the post-ARP Act rebate environment. The organization's true pass-through payment model exemplifies a commitment to fair and transparent dealings, which may become an industry standard in the wake of the ARP Act's changes. Health Delegates' approach could prompt other industry players to adopt similar transparent practices, fostering a more open and predictable rebate market.

Looking ahead: preparing for a new era of rebates

The ARP Act's AMP cap removal is set to ripple through the rebate system, impacting Medicaid and beyond, marking a transformative period in the pharmaceutical industry. As the industry approaches the January 2024 threshold, it is imperative for all stakeholders, including manufacturers, healthcare providers, and payers, to grasp the full scope of these changes. The healthcare sector must remain agile, strategic, and proactive to successfully navigate the new financial landscapes that will emerge from this significant policy shift. The coming years will likely see a period of adjustment as the market responds to the new pricing and rebate structures, with long-term implications for drug pricing, market competition, and patient access.

Health Delegates' commitment to our clients

At Health Delegates we work with our clients to understand this impact and ensure you have information on how this may impact your rebate dollars. We arm you with information to alleviate the uncertainty. As changes are implemented in 2024, we will continue to keep our finger on the pulse and communicate possible impacts.

Decoding Rebate Realities

Thu, 28 Sep 2023 20:56:14 GMT

A comprehensive guide to evaluating your score

EXECUTIVE SUMMARY

Navigating the intricacies of the United States healthcare system poses a significant challenge, with issues like rising prescription drug costs, premium hikes, treatment suitability, accessibility concerns, and complex coverage strategies in the spotlight. Among these, pharmacy benefit management and rebates have surged to the forefront of discussions, prompting critical evaluation at every level. With increasing attention on drug rebates and their impact, it is imperative for healthcare entities to uncover the truth behind these often-misunderstood incentives.

As drug rebates continue to be a focal point of interest and raise a barrage of questions for healthcare plans and stakeholders it’s critical to actively investigate your source. How can plans ensure that the rebates they receive align with their actual utilization? Is maximizing rebates the priority or does a tightly managed formulary offer superior benefit? The road ahead demands a shift in perspective – an urge to probe deeper and ask more questions, as healthcare transformation propels patients to make informed treatment choices.

Download our whitepaper

Bypass the Band-aid Approach to Lowering Specialty Drug Costs: A Carve-Out Can Help You Improve Access to Plan Members and Save Your Bottom Line

Tue, 08 Jun 2021 18:51:00 GMT

Specialty medications today cost an average of 10 to 15 times more than traditional brand drugs. And, within a year, specialty pharmacy will account for approximately 47 percent of the pharmacy industry’s overall expenditures. (1) With an aging employee population comes more chronic and complex health conditions that require specialty medications. As a result, associated expenditures will continue to increase with no immediate end in sight.

In an effort to combat and contain rising costs, employers have seen a wave of “Band-aid” approaches flood the market place. These include Patient Assistance Programs (also known as PAP), copay cards and specialty medication exclusions. While, at the surface, some of these approaches may improve patient adherence by shaving off some out-of-pocket costs for plan members, the mechanisms that drive them are often temporary with expiration dates, complicated qualifiers and limited funds that — you guessed it — can run out.

PAP Programs

A lifesaver for some, particularly people facing large medical bills, and a controversial Band-aid approach to others. Known as a “safety net,” PAP programs are funds sponsored by pharmaceutical manufacturers, states or nonprofit organizations for people with no health insurance or who are underinsured. When a PAP program is clinically indicated and managed well, it can be life changing and even lifesaving.

Pros

Provides financial assistance to people to access medications for little or no out-of-pocket costs.

Cons

In some instances, it’s a Band-aid approach. It can help with some costs, but not indefinitely.
Eligibility can vary and include income and residency exclusions. In addition, not all funds freely disclose eligibility criteria, making it difficult for people to understand if they can qualify or not.
Registration can be confusing and tedious for many people to navigate.
Can lock people into specific drug brands, even when less expensive alternatives are available.
Funds run out and, without proper oversight, can expire during treatment leaving people with surprise expenses.

Copay Cards

Think of copay cards as a coupon or discount card that provides plan users with a front-end discount off of their specialty drug copayments.

Pros:

They lower out-of-pocket costs at the cash register. A copay card can offer instant reimbursements up to a certain, predefined dollar amount — for example $100 off of a $144 copayment. (2)
With these discounts, members tend to fill their prescriptions more regularly, thereby, improving adherence.

Cons:

It’s a Band-aid approach. While it all sounds great on the front-end, there’s no such thing as free money. Those discounts come at a cost. Manufacturers tend to offer copay discounts on higher cost brand names to compete with competing lower-priced options. When this occurs, the discount savings are passed on to the insurer, which ultimately yields higher premium costs.
In addition, copay cards have expiration dates. Some of the more generous programs offer discounts on a few medication fills. But when the card expires, so do the discounts. Then, the plan member goes back to square one.

Specialty Pharmacy Exclusions

Among the more drastic cost saving measures is the exclusion of specialty medication coverage. In this instance, an insurance plan excludes specialty medications completely from the covered benefit, leaving plan members to fend for themselves. When the plan uses exclusion to eliminate costs for specialty medications, plan members are unable to get drug discounts and cannot request exceptions or medical necessity. Compounding the issue, the contracting employer has little-to-no power to overturn coverage denials.

Pros and Cons

On the front end, plan premiums may be lowered. On the back end, this Band-aid approach can significantly compromise plan members’ access to necessary specialty medications.

Bypass the Band-aid Approach with a Specialty Pharmacy Carve Out

A more holistic approach that can help solve cost-containment needs for all parties — from plans, to employers, to plan members — from the ground up, is the specialty pharmacy carve-out program.

A specialty pharmacy carve-out is a program that pulls, or “carves out” specialty drugs from a medical plan benefit, then transfers and administers this coverage through a third-party provider.

Benefits

Drives improved member access to specialty drugs at lower costs without impacting premiums and other costs.
Avoids temporary cost fixes that will expire or run out.
Provides greater employer transparency into pharmacy benefits to control spending, negotiate better deals and ensure optimal program performance.
Enables the provision of a complete pharmacy benefits program that satisfies plan members and stays within an employer’s financial guardrails.

Ready to remove the Band-aid? Let Health Delegates help you build the ideal specialty pharmacy carve-out program for your organization. One call can get you on the path to covering your employees’ specialty pharmacy needs and protecting your bottom line.

We can help. Contact us today .

Sources:

(1) https://www.pharmacytimes.com/view/cost-of-dispensing-specialty-drugs-may-be-more-than-you-think

(2) https://www.statnews.com/2016/09/14/pros-cons-drug-coupon-cards/

Market-Changing Deals: What You Should Know

Tue, 08 Jun 2021 18:32:00 GMT

As Charles Dickens once wrote, “Change begets change. Nothing propagates so fast.”

Truer words have probably never been written.

It doesn’t take much to see that, over the past year, there has been nothing but change – both big and small, in the healthcare space – particularly in pharmacy and benefits. And when it comes to drug channels and how some key players are poised to disrupt the market in a big way, there is no shortage of change-making-deals. The question is: How will these changes affect insurers, pharmacies, and health plans?

Rebate & Healthcare Market ChangesReinventing the Market through Contract Language

We’ve written other blogs about contracts and how the language used is often chosen to specifically create favorable conditions for one sector over another. This isn’t a surprise, it’s the first rule of contract writing. That’s why there are experts who review and negotiate contracts – so that people can be sure their best interests are also being taken into account.

However, when companies “collaborate” to deliver more affordable care to consumers, and structure the details of that collaboration in a way that leverages the enormous volume of consumers they serve to create an environment that gives them maximum negotiating power, someone is going to have to carry the burden of higher pricing. And that will fall squarely on the shoulders of pharmacies and health plans on the receiving end of the new market scale that is created.

Some key implications of these types of contracts include:

Manufacturers and pharmacies can face increased PBMs and those increases can be significant. There could be a further muddying of transparency in underlying economics

Collaborations are harder for the Federal Trade Commission (FTC) to challenge creating a

situation ripe for manipulation by key players.

What These Changes Mean for the Market Increasing PBMs

Healthcare is notoriously slow to change – but change is inevitable. And some deals could very well be seen as pro-competitive by the FTC because of its potential to lower healthcare costs and be beneficial to consumers.

But at what cost?

When the checks and balances we normally see at work are stilled, the pendulum can swing wildly. Staying on top of how the rebate and healthcare market changes will give you a head’s up on what changes might be on the horizon and how collaborative ventures can propel those changes.

It’s a slippery slope, and one that needs to be navigated with great care and expertise.

Here at Health Delegates one of our main goals is to keep our customers informed. Subscribe to our blog today and stay up-to-date on market changes, deals, and ventures that have the potential to impact your bottom line.

Rebate Contract Language: What They’re Not Telling You

Wed, 02 Jun 2021 22:43:00 GMT

As drug rebates continue to grow more complex, many health organizations are getting stuck in the red tape of rebate “partners.” Others give up and simply trust that they were able to secure a benevolent or altruistic rebate partner.

Unfortunately, with many rebate aggregators favoring opaque manufacturer rebate arrangements, altruism and money are down the drain. But, there are a few things you can keep in mind that may help navigate these murky waters and keep you from leaving money on the table.

Know the pros and cons of a pass-through model v. a guaranteed model

This is the first step in arming yourself against potentially money-losing rebate arrangements and contracts. For example, a pass-through model may seem ideal, but do you really know what (or who) is driving those rebate aggregators? And, in comparison, a guaranteed or fixed model may seem dependable, but do you know if you are getting capped on your rebates? Clarification on key points can save you a lot of money.

Stay educated

This is a great second step. Staying educated on the gray areas of contract terms and language, where unfair financial advantages may be lurking under the radar, can help you avoid making assumptions about what your rebates might be, which can put lowering your overall drug spend in jeopardy.

Remember – the answer to a lower drug spend may be neither model

It’s true. Sometimes, the best way to lower a drug spend might be to simply forgo a rebate all together. Things like when there’s a:

Generic equivalent is available

Clinically the rebated drug does not have the same efficacy or if the

Cost of a non-rebated drug is less

Demand clarity

Look for a rebate aggregator who will accept the challenge of rethinking the link between data and dollars and provide their customers with more actionable insights and control over the net drug costs. Getting access to a formulary that optimizes rates, rebates, copays, and discounts – and shows you exactly where your rebates are earned, right down to the claim and NDC level, is just one level of transparency that will provide the insights needed to turn action into dollars.

Chasing rebates can be a nightmare of formulary audits and, even after expending all that energy, there is still no guarantee that you are going to get the best price – with or without a rebate – in order to see that net drug spend decrease.

So, remember, as the saying goes, “If it sounds too good to be true, it probably is.”

If you suspect your contract terms are not focused on your best interests, consider going back to the negotiating table. You deserve to know exactly what you are getting. Whether you are a health plan, a PBM, or an employer group, you need a partner who can see through opaque contracts -- before you can sign them – and provide you the transparency and clarity necessary to get you the lowest costs possible.